Does the DPP4 Inhibitor (Sitagliptin) Increase Endometrial Mesenchymal Stem Cells in Women with Recurrent Miscarriage?

niversity Hospitals Coventry and Warwickshire NHS Trust0 个研究点目标入组 38 人开始时间: 2016年12月19日最近更新: 2020年6月29日

适应症

试验速览

暂无简介。

•1. Provision of informed written consent
•2. History of recurrent miscarriage - 3 or more miscarriages (three or more spontaneous pregnancy losses prior to 24 weeks gestation)
•3. Age 18-42 years at consent
•4. Any BMI – no dose adjustment needed for BMI. BMI has no clinically meaningful effect on the pharmacokinetics of Sitagliptin.
•5. Willing and able to give consent for the study and endometrial biopsy.
•6. Ability to fully understand the requirements of the protocol
•7. Adequate renal function , defined as Urea 2.5 – 7.8mmol/L, Creatinine 50 -90umol/L, potassium 3.5 – 5.3mmol/L, Sodium 133 -146mmol/L
•8. Adequate hepatic function, defined as total protein 60 – 80g/L, Albumin 35-50g/L, Bilirubin 4-20umol/L, Alkaline Phosphatase (ALP) 35-105U/L, Alanine Transferase (ALT) 5-38 U/L
•9. Negative pregnancy test on the day of randomisation

•1. Under 18 years of age – the safety and effectiveness of Sitagliptin in paediatric patients under 18 has not yet been established
•2. Type I Diabetes – Sitagliptin should not be used in type 1 diabetes
•3. Type II Diabetes – based on medical history
•4. Pregnancy (tested at multiple points in trial)
•5. Breast feeding – Caution is advised when prescribing Sitagliptin to breastfeeding mothers as it is not known if it is secreted in breast milk.
•6. Known hypersensitivity to Sitagliptin
•7. Not taking any medications with potential to react with interventional product:
•7.1. Digoxin –plasma monitoring is needed if Sitagliptin used concomitantly in those at risk of digoxin toxicity
•7.2. Enalapril – Sitagliptin appears to alter the hypotensive effects of enalapril
•8. Previous diagnosis of pancreatitis
•9. Renal impairment with eGFR<50 mL/min
•10. Liver impairment, defined as any value out of normal range (total protein 60 – 80g/L, Albumin 35-50g/L, Bilirubin 4-20umol/L, Alkaline Phosphatase (ALP) 35-105U/L, Alanine Transferase (ALT) 5-38 U/L)
•11. Inclusion in another intervention trial
•12. Unwilling to use effective contraception for the duration of the trial (from consent)
•13. Allergy/sensitivity to excipients of the IMP/placebo

发起方

niversity Hospitals Coventry and Warwickshire NHS Trust